The effects of hydroxychloroquine on endothelial dysfunction

Pregnancy Hypertension

Volumn 6, Issue 4, 2016, Pages 259-262

  Rahman, Rahana ^a,b,c   Murthi, Padma ^b   Singh, Harmeet ^a   Gurusinghe, Seshini ^a,b   Mockler, Joanne C ^a,b   Lim, Rebecca ^a   Wallace, Euan M ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Endothelial dysfunction; Endothelin 1; Hydroxychloroquine; Preeclampsia; Preeclamptic serum; TNF

Indexed keywords

ENDOTHELIN 1; HYDROXYCHLOROQUINE; TUMOR NECROSIS FACTOR; ANTIMALARIAL AGENT;

ADJUVANT THERAPY; ADULT; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MORBIDITY; MORTALITY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; METABOLISM; PREGNANCY; PRIMARY CELL CULTURE; SERUM; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIMALARIALS; ENDOTHELIN-1; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYCHLOROQUINE; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PRIMARY CELL CULTURE; SERUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006272235     PISSN: 22107789     EISSN: 22107797     Source Type: Journal    
DOI: 10.1016/j.preghy.2016.09.001     Document Type: Article

References (25)

1. [1] Steegers, E.A.P., von Dadelszen, P., Duvekot, J.J., Pijnenborg, R., Pre-eclampsia. Lancet 376 (2010), 631–644.
2. [2] Ananth, C.V., Vintzileos, A.M., Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am. J. Obstet. Gynecol. 195 (2006), 1557–1563.
3. [3] Redman, C.W., Sargent, I.L., Latest advances in understanding preeclampsia. Science 308 (2005), 1592–1594.
4. [4] Sibai, B., Dekker, G., Kupferminc, M., Pre-eclampsia. Lancet 365 (2005), 785–799.
5. [5] Roberts, J.M., Hubel, C.A., Oxidative stress in preeclampsia. Am. J. Obstet. Gynecol. 190 (2004), 1177–1178.
6. [6] Bridges, J.P., Gilbert, J.S., Colson, D., Gilbert, S.A., Dukes, M.P., Ryan, M.J., Granger, J.P., Oxidative stress contributes to soluble Fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am. J. Hypertens. 22 (2009), 564–568.
7. [7] Maynard, S.E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T.A., Morgan, J.P., Sellke, F.W., Stillman, I.W., Epstein, F.H., Sukhatme, V.P., Karumanchi, S.A., Excess placental soluble fms-like tyrosine kinsase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111 (2003), 649–658.
8. [8] Venkatesha, S., Toporsian, M., Lam, C., Hanai, J.-I., Mammoto, T., Kim, Y.M., Bdolah, Y., Lim, K.-H., Yuan, H.-T., Libermann, T.A., Stillman, I.E., Roberts, D., D'Amore, P.A., Epstein, F.H., Sellke, F.W., Roberto, R., Sukhatme, V.P., Letarte, M., Karumanchi, S.A., Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12 (2006), 642–649.
9. [9] Levine, R.J., Lam, C., Qian, C., Yu, K.F., Maynard, S.E., Sachs, B.P., Sibai, B.M., Epstein, F.H., Romero, R., Thadhani, R., Karumanchi, S.A, Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355 (2006), 992–1005.
10. [10] Lim, R., Acharya, R., Delpachitra, P., Hobson, S., Sobey, C.G., Drummond, G.R., Wallace, E.M., Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am. J. Obstet. Gynecol., 212, 2015 86.e1-12.
11. [11] Hobson, S.R., Acharya, R., Lim, R., Chan, S.T., Mockler, J., Wallace, E.M., Role of activin A in the pathogenesis of endothelial cell dysfunction in preeclampsia. Pregnancy Hypertens. 6 (2016), 130–133.
12. [12] Gurusinghe, S., Wallace, E., Lim, R., The relationship between Activin A and anti-angiogenic factors in the development of pre-eclampsia. Pregnancy Hypertens. 4 (2014), 3–6.
13. [13] Mihu, D., Razvan, C., Malutan, A., Mihaela, C., Evaluation of maternal systemic inflammatory response in preeclampsia. Taiwan J. Obstet. Gynecol. 54 (2015), 160–166.
14. [14] Bartha, J., Romero-Carmona, R., Comino-Delgado, R., Inflammatory cytokines in intrauterine growth retardation. Acta Obstet. Gynecol. Scand., 82, 2003, 1099.
15. [15] Moreli, J.B., Correa-Silva, S., Damasceno, D.C., Sinzato, Y.K., Lorenzon-Ojea, A.R., Borbely, A.U., et al. Changes in the TNF-alpha/IL-10 ratio in hyperglycemia-associated pregnancies. Diabetes Res. Clin. Pract. 107 (2015), 362–369.
16. [16] Zhang, H., Park, Y., Wu, J., Chen, X., Lee, S., Yang, J., et al. Role of TNF-alpha in vascular dysfunction. Clin. Sci. (Lond) 116 (2009), 219–230.
17. [17] Cigni, A., Pileri, P.V., Faedda, R., Gallo, P., Sini, A., Satta, A.E., et al. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor alpha in active and quiescent systemic lupus erythematosus. J. Invest. Med. 62 (2014), 825–829.
18. [18] Yoshio, T., Masuyama, J., Mimori, A., Takeda, A., Minota, S., Kano, S., Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 54 (1995), 361–365.
19. [19] Gomez-Guzman, M., Jimenez, R., Romero, M., Sanchez, M., Zarzuelo, M.J., Gomez-Morales, M., et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension 64 (2014), 330–337.
20. [20] Willis, R., Seif, A.M., McGwin, G. Jr., Martinez-Martinez, L.A., Gonzalez, E.B., Dang, N., et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21 (2012), 830–835.
21. [21] Lowe, S., Bowyer, L., Lust, K., McMahon, L., Morton, M., North, R., et al. Guidelines for the management of hypertensive disorders of pregnancy. Aust. N.Z. J. Obstet. Gynaecol. 49:2014 (2014), 242–246.
22. [22] Mandang, S., Manuelpillai, U., Wallace, E.M., Oxidative stress increases placental and endothelial cell activin A secretion. J. Endocrinol. 192 (2007), 485–493.
23. [23] Arnaoutova, I., Kleinman, H.K., In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat. Protoc. 5 (2010), 628–635.
24. [24] Saleh, L., Verdonk, K., Visser, W., van der Meiracker, A., Danser, A.J., The emerging role of ET-1 in the pathogenesis of PE. Ther. Adv. Cardiovasc. Dis., 2016, 10.1177/1753944715624853.
25. [25] LaMarca, B.B., Cockrell, K., Sullivan, E., Bennett, W., Granger, J.P., Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46 (2005), 82–86.